Crizotinib was approved by the U.S. Food and Drug Administration for the treatment of ALK rearrangement-positive NSCLC in 2011, and a recent report has addressed the clinical efficacy of this agent in a clinical practice setting [59]. Here, ALK is linked to non-small cell lung carcinoma.